Company Overview and News
Stop missing out on important events!
The following slide deck was published by Erytech Pharma S.A. ADS in conjunction with this event. (0-1)
The following slide deck was published by Erytech Pharma S.A. ADS in conjunction with their 2017 Q4 earnings call.
ERYTECH Pharma SA (OTC:EYRYY) Q4 2017 Results Earnings Conference Call March 13, 2018 8:30 AM ET
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. (945-6)
The JPMorgan Healthcare Conference is a significant event that readers interested in the sector should pay close attention to. (66-5)
I revisit the bullish thesis below and remind readers of two upside driveres, ALL and pancreatic cancer. (23-6)
Its unique technology platform ERYCAPS has allowed it to develop a promising pipeline of candidates developed by encapsulating therapeutic drug substances inside red blood cells. (44-1)
Erytech Pharma (OTC:EYRYY) has 1 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 4,898,337 shares. Largest shareholders include Baker Brothers Advisors LP. (0-7)
Ten companies raised a combined $1.6 billion in the most active week of the 2017 IPO market. Texas community bank CBTX took the top spot with a 10% pop, which is still below the long-term historical average of 13%. The week featured three regional banks, three biotechs, three fast-growing Chinese companies and a communications platform pivoting to growth. First-day pops for IPOs this week averaged just 3. (36-5)
Nov 8, 2017 - PRICED: Apellis Pharmaceuticals (US, biotech) – $150m IPO. 10.71m shares (100% prim) at$14 versus marketing at $13-$15. CITI, JPM. Cadence Bancorp (US, commercial bank) – $209m FO. 9.5m shares (100% sec) at $22.00 versus $23.00 last sale and $25.46 launch. GS, JPM. Sogou (Cayman Islands/China, internet search) – $585m IPO. 45m ADSs (100% prim) at $13.00 versus marketing at $11-$13. JPM, CS, GS, CICC, CREN. (33-0)
The U.S. IPO market is sizzling this week with 11 deals that will collectively raise more than $2 billion. This will mark the busiest week of this year. In particular, the Chinese companies have been at the forefront with the second-largest mobile search engine Sogou (SOGO) expected to go public on Nov 9. The company plans to raise $540 million at a market capitalization of $4.8 billion (read: What Lies Ahead for China Tech ETFs?). (0-1)
Yesterday, we noted that Valeant Pharmaceuticals is giving Addyi, the female libido drug dubbed ‘the female Viagra,’ back to its former owners. This is quite a big deal as Valeant bought Sprout Pharmaceuticals, the company behind the drug for a whopping $1 billion just over two years ago. (38-0)
The steady flow of IPOs in the 4Q is set to continue with six companies in six different sectors scheduled to raise a combined $2.1 billion in the week ahead. The diverse collection includes unicorn ForeScout Technologies (Private:SCOUT), an enterprise security software provider that hopes to follow the success of the most recent unicorn to IPO, MongoDB (Pending:MDB), which priced last week and popped 34% on its first day. (49-0)
Erytech Pharma established a research collaboration with Queen’s University in Canada to support continued preclinical development of its eryminase candidate for treating the rare metabolic disorder arginase-1 deficiency. Eryminase comprises the enzyme arginine deiminase encapsulated in red blood cells using Erytech’s proprietary Erycaps platform technology.
SAN DIEGO, Jan. 18, 2017 /PRNewswire/ -- Invetech, the leading developer of cGMP manufacturing solutions for cell and advanced therapies, has announced a collaboration agreement with Erytech Pharma, the French biopharmaceutical company developing "tumor starvation" treatments for acute leukemia and other oncology indications with unmet medical needs. Under the agreement, Invetech will develop systems to enable the commercial-scale manufacture of products based on Erytech's proprietary ERYCAPS technology platform, which uses a novel technology to encapsulate therapeutic drug substances inside red blood cells and is designed to more effectively deliver therapeutics with reduced side effects.